The winners of today might not compete in the lucrative new segment of tomorrow.Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, AstraZeneca's (AZN 0.75%) CEO, Pascal Soriot, recently made some interesting remarks during the company's second-quarter earnings call with analysts.Soriot's view has major implications for how investors should approach stocks like AstraZeneca, as well as weight loss drug leaders like Novo Nordisk and Eli Lilly -- not to mention b ...

These stocks arguably deserve more respect from investors.The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely.Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to buy right now. Here's why they picked AstraZeneca (AZN 0.38%), Pfizer (PFE 3.21%), and Viatris (VTRS 2.08%).A healthcare behemoth that's trading at a discountDavid Jagielski (AstraZeneca): You wou ...

AstraZeneca TodayAZNAstraZeneca$78.52 -1.19 (-1.49%) 52-Week Range$60.47▼$80.86Dividend Yield2.46%P/E Ratio38.49Price Target$88.00Add to WatchlistAstraZeneca PLC NASDAQ: AZN is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%. The total return of the SPDR S&P Pharmaceuticals ETF NYSEARCA: XPH is 4%.Let's review the company’s business ...

Wall Street has rewarded certain growth stocks handsomely this year. I believe now may be an opportune time to buy some of these high-flyers, even after the recent tech selloff. Most of the stocks I’ll be discussing today are outside the tech sector. I think they have a great chance to continue their upward trajectory.These companies boast impressive top-line growth metrics. Their stocks have also demonstrated remarkable consistency over time. If they keep executing as they historically have, I expect explo ...

AstraZeneca PLC (NASDAQ:AZN) Q2 2024 Earnings Conference Call July 25, 2024 6:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - Executive Director & CEO Aradhana Sarin - Executive Director & CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology Research and Development Ruud Dobber - EVP & President, BioPharmaceuticals Sharon Barr - EVP, BioPharmaceuticals Research and Development Marc Dunoyer - CEO, Alexion and Chief Strategy Officer, AstraZeneca Dave Fredrickson ...

The chief executive of AstraZeneca has criticised a public health body for refusing to make one of its breast cancer treatments available to NHS patients in England and Wales.The National Institute for Health and Care Excellence (NICE) decided in March this year that patients should be denied access to Enhertu because it said the drug did not provide value for money. Money blog:' Major boost' for borrowers as two banks cut mortgage ratesBut Sir Pascal Soriot said he was disappointed at the decision - which ...

The British drugmaker's Q2 results were good, but seemingly not good enough for many investors.Shares of AstraZeneca (AZN -2.70%) were sliding 3.2% lower as of 10:57 a.m. ET on Thursday. The decline came after the British drugmaker announced its second-quarter results.AstraZeneca reported total revenue in Q2 of $12.9 billion, up 13% year over year. This result topped the average analysts' revenue estimate of $12.6 billion.The company posted earnings per share (EPS) of $1.24, a 6% year-over-year increase. It ...

For the quarter ended June 2024, Astrazeneca (AZN) reported revenue of $12.94 billion, up 13.3% over the same period last year. EPS came in at $0.99, compared to $1.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $12.48 billion, representing a surprise of +3.70%. The company delivered an EPS surprise of +3.13%, with the consensus EPS estimate being $0.96.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

AstraZeneca’s (AZN) second-quarter 2024 core earnings of 99 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 96 cents. Core earnings of $1.98 per share fell 8% year over year on a reported basis and 3% at constant exchange rates (CER).Total revenues of $12.94 billion rose 13% on a reported basis and 17% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $12.48 billion.All ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA England Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is sub ...